Cargando…

Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms

BACKGROUND: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Mingomataj, Ervin, Priftanji, Alfred, Qirko, Etleva, Dinh, Q Thai, Fischer, Axel, Peiser, Christian, Groneberg, David A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128821/
https://www.ncbi.nlm.nih.gov/pubmed/12201901
_version_ 1782120338872598528
author Mingomataj, Ervin
Priftanji, Alfred
Qirko, Etleva
Dinh, Q Thai
Fischer, Axel
Peiser, Christian
Groneberg, David A
author_facet Mingomataj, Ervin
Priftanji, Alfred
Qirko, Etleva
Dinh, Q Thai
Fischer, Axel
Peiser, Christian
Groneberg, David A
author_sort Mingomataj, Ervin
collection PubMed
description BACKGROUND: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymenoptera venom in the mediterranean population of Albania. METHODS: A retrospective study was performed using the clinical reports of 37 patients with venom of bee (apinae), wasp (vespidae, subfamily vespinae) or paperwasp (vespidae, subfamily polistinae) allergy treated with Rush-SIT between 1987 and 1996. After hymenoptera sting allergy diagnosis according to anamnesis and intracutaneous tests the patient were treated with Rush-SIT. The protocol lasted 3 – 4 d with an increase in the concentration from 0.01 μg/ml to 100 μg/ml. Anaphylactic reactions were classified according to the Mueller-classification. RESULTS: The frequency of reactions during Rush-SIT for bee-venom was 4.7% and for wasp-venom was 1.5% (p < 0.01). The mean frequency of reactions of Mueller grade II for the bee-venom Rush-SIT patients during the first 4 d (= 26 injections) was 0.73 and for the wasp-venom Rush-SIT patients 0.15. No patient experienced a third-degree reaction. 94.6% of the patient supported an end dose of 100 μg. CONCLUSIONS: Rush-SIT is a reliable method for the treatment of anaphylactic reactions to hymenoptera venom even in less developed countries. Bee-venom Rush-SIT was found to cause higher numbers allergic reactions than wasp or paperwasp Rush-SIT.
format Text
id pubmed-128821
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1288212002-10-23 Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms Mingomataj, Ervin Priftanji, Alfred Qirko, Etleva Dinh, Q Thai Fischer, Axel Peiser, Christian Groneberg, David A BMC Dermatol Research Article BACKGROUND: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymenoptera venom in the mediterranean population of Albania. METHODS: A retrospective study was performed using the clinical reports of 37 patients with venom of bee (apinae), wasp (vespidae, subfamily vespinae) or paperwasp (vespidae, subfamily polistinae) allergy treated with Rush-SIT between 1987 and 1996. After hymenoptera sting allergy diagnosis according to anamnesis and intracutaneous tests the patient were treated with Rush-SIT. The protocol lasted 3 – 4 d with an increase in the concentration from 0.01 μg/ml to 100 μg/ml. Anaphylactic reactions were classified according to the Mueller-classification. RESULTS: The frequency of reactions during Rush-SIT for bee-venom was 4.7% and for wasp-venom was 1.5% (p < 0.01). The mean frequency of reactions of Mueller grade II for the bee-venom Rush-SIT patients during the first 4 d (= 26 injections) was 0.73 and for the wasp-venom Rush-SIT patients 0.15. No patient experienced a third-degree reaction. 94.6% of the patient supported an end dose of 100 μg. CONCLUSIONS: Rush-SIT is a reliable method for the treatment of anaphylactic reactions to hymenoptera venom even in less developed countries. Bee-venom Rush-SIT was found to cause higher numbers allergic reactions than wasp or paperwasp Rush-SIT. BioMed Central 2002-08-30 /pmc/articles/PMC128821/ /pubmed/12201901 Text en Copyright © 2002 Mingomataj et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Mingomataj, Ervin
Priftanji, Alfred
Qirko, Etleva
Dinh, Q Thai
Fischer, Axel
Peiser, Christian
Groneberg, David A
Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms
title Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms
title_full Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms
title_fullStr Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms
title_full_unstemmed Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms
title_short Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms
title_sort specific immunotherapy in albanian patients with anaphylaxis to hymenoptera venoms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128821/
https://www.ncbi.nlm.nih.gov/pubmed/12201901
work_keys_str_mv AT mingomatajervin specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms
AT priftanjialfred specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms
AT qirkoetleva specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms
AT dinhqthai specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms
AT fischeraxel specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms
AT peiserchristian specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms
AT gronebergdavida specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms